



8-19-02

GP1653

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-448-A)

In the Application of:

Rodgers and diZerega

Serial No.: 09/723,255

Filing Date: November 27, 2000

For: Methods for Treating and Preventing
Alopecia

Examiner: Chism

Group Art Unit: 1653

RECEIVED

AUG 20 2002

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Asst. Commissioner for Patents
Box: RESPONSE
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- ☒ Transmittal Letter (1 sheet);
- ☒ Response to Office Action Mailed July 15, 2002 (3 sheets);
- ☒ Return Receipt Postcard


2. With respect to fees:

- a) No fee is required.
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. **CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10:** The undersigned hereby certifies that this Transmittal Letter and the papers, as described hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Asst. Commissioner for Patents, Box RESPONSE, Washington, D.C. 20231, on this 15th day of **August, 2002**.

Express Mail No. **EL904278939US**.

Respectfully submitted,


David S. Harper

Registration No. 42,636



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-448-A)

[Handwritten signatures]
PATENT
RECEIVED
AUG 20 2002
TECH CENTER 1600/2900

In the Application of:

Rodgers and diZerega

Serial No.: 09/723,255

Filing Date: November 27, 2000

For: Methods for Treating and Preventing Alopecia

Examiner: Chism

Group Art Unit: 1653

RESPONSE TO THE OFFICE ACTION MAILED JULY 15, 2002

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENTS

In the claims:

Please cancel claims 12 and 14

al 11. (Amended) The method of claim 1 wherein the active agent comprises the sequence SEQ ID NO:41.

as 13. (Amended) The method of claim 1 wherein the active agent consists of the sequence of SEQ ID NO:41.

REMARKS

In response to the office action mailed July 15, 2002, the Applicants herewith elect the invention of Group I, claims 1-16 drawn a method of treating alopecia. The Applicants further elect the method using SEQ ID NO:41 (NorLeu-AII(1-7)). During a telephone conference with the Examiner on August 14, 2002, the Examiner stated that generic claims encompassing the elected peptide would be considered. All of the pending claims encompass the use of SEQ ID NO:41.